Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.
You're using version {0} of the web browser {1}. This means that the content or functionality of our website may be limited or unavailable. We recommend that you upgrade your browser to optimise your experience of our website.
A novel type of immunoblocking as a means to cure autoimmunne diseases
| Reference number | 2009-00463 |
| Coordinator | Holdingbolaget vid Göteborgs universitet AB - GU Holding Kompetens AB |
| Funding from Vinnova | SEK 900 000 |
| Project duration | April 2009 - September 2010 |
| Status | Completed |
